Tabled the DANK Cannabis Research Bill Tabled in US Congress

In another case of US lawmakers proving their ability to hilariously name their proposed acts, the DANK Cannabis Research bill has just been tabled. And while we can’t confirm whether the name was intentional or not, we do know what it proposes. In short, it introduces a range of measures that aim to speed up cannabis research efforts, particularly with respect to certain use cases.

Congressional lawmakers on Wednesday introduced a bill named the DANK Cannabis Research bill. The bill will establish a federal cannabis research program and allow universities to conduct cannabis studies with federal grants.

For more news like this from the US and around the world, download our free cannabis news app.

Was the DANK Title Intentional?

The text is titled Developing And Nationalizing Key Cannabis Research Act, with the first four initials being highly-evocative (in case you didn’t know, DANK designates strong, sticky, and well-structured cannabis). However, we still don’t know if it was intentional or not.

A DANK Research Agenda

Either way, DANK would require the National Institutes of Health (NIH) to work with other agencies, including the Centers for Disease Control and Prevention (CDC) and the Substance Abuse and Mental Health Services Administration (SAMHSA), to develop “a national cannabis research agenda that addresses key questions and evidence gaps.”

This program should include six main research objectives. For example, under DANK, agencies should prioritize studies on the safety and effectiveness of cannabis in treating multiple diseases such as epilepsy, multiple sclerosis, chemotherapy-related pain, and nausea caused by chemotherapy, as well as use as an alternative to opioids.

Other items on the DANK agenda include research on the effects of cannabis on “at-risk populations” such as children and pregnant women, the “non-therapeutic effects” of cannabis, the relationship between cannabis use and behavioral health, “clinically appropriate cannabis dosages and modes of administration,” and other public safety considerations related to potency, youth access, and abuse.

Congress Is Speeding Up Cannabis Research

The tabling of this new legislation comes the same week the U.S. House of Representatives separately voted to approve another bipartisan cannabis research bill that also aims to speed up and simplify the process of obtaining necessary permissions. This measure, which would not allow researchers to study cannabis from dispensaries, unlike the DANK Act, should be quickly taken up by the Senate before possibly being sent to President Joe Biden’s desk.

—

(Featured image by DANK Research (CC BY-NC-SA 4.0) via Seedfinder)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published by Newsweed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions, or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.